pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 3 · small molecule · Achondroplasia
Voxzogo (vosoritide) is a subcutaneous injection approved for achondroplasia, the most common form of genetic dwarfism. Developed by BioMarin Pharmaceutical Australia Pty Ltd, vosoritide is a C-type natriuretic peptide (CNP) analog that works by activating natriuretic peptide receptor B (NPR-B) to promote bone growth a
Internal code 111-302
Voxzogo (vosoritide) is a subcutaneous injection approved for achondroplasia, the most common form of genetic dwarfism. Developed by BioMarin Pharmaceutical Australia Pty Ltd, vosoritide is a C-type natriuretic peptide (CNP) analog that works by activating natriuretic peptide receptor B (NPR-B) to promote bone growth and improve linear growth velocity in children with achondroplasia. The compound represents a mechanistic advance in treating a rare genetic skeletal dysplasia affecting approximately 1 in 25,000 live births.
Voxzogo has achieved regulatory approval across major markets: approved in Australia (May 2023), the European Union (November 2025), and the United States. The current development activity centers on a Phase 3 open-label long-term extension study (NCT 2023-508864-31-00) designed to evaluate safety and efficacy in the pediatric achondroplasia population. BioMarin's strategy emphasizes long-term safety surveillance and real-world efficacy data collection in children receiving ongoing treatment.
The drug is marketed in three formulation strengths (0.4 mg, 0.56 mg, and 1.2 mg powder for injection) and carries Australian PBS listings (codes 13270K, 13274P, 13275Q), indicating government-subsidized access. Regulatory approval across the US, EU, and Australia establishes Voxzogo as the first and currently only CNP analog therapy for achondroplasia in these jurisdictions, addressing a previously untreated indication with significant unmet medical need in the pediatric population.
Achondroplasia is a rare genetic disorder causing severe growth restriction and skeletal abnormalities with no disease-modifying therapies available prior to vosoritide approval. Affected children experience progressive complications including short stature, spinal stenosis, and orthopedic deformities that substantially impact quality of life and functional outcomes. The condition affects an estimated 250,000 individuals globally, with approximately 25,000 new cases annually, yet therapeutic options have historically been limited to symptomatic management and surgical intervention.
Voxzogo's approval represents a paradigm shift in achondroplasia management by offering the first pharmacological intervention targeting the underlying pathophysiology. The drug addresses a substantial unmet medical need in pediatric populations where growth velocity improvements translate directly to functional and psychosocial benefits. Market relevance is heightened by the chronic, lifelong nature of achondroplasia and the pediatric treatment window during which growth velocity can be meaningfully modified.
Competitive positioning is currently favorable, as Voxzogo appears to be the only CNP analog approved for achondroplasia globally. The competitive landscape includes growth hormone therapy (off-label use) and supportive care approaches, but no other disease-modifying pharmacological agents. Government reimbursement in Australia via PBS listing indicates payer recognition of clinical and economic value. The commercial opportunity encompasses the entire pediatric achondroplasia population across approved markets, with potential for label expansion to adult populations and additional indications in related skeletal dysplasias.
Drug Class: C-type natriuretic peptide (CNP) analog; classified under Musculo-skeletal system (M05) therapeutic category.
Mechanism of Action: Vosoritide activates natriuretic peptide receptor B (NPR-B), a guanylate cyclase-coupled receptor expressed in growth plate cartilage. Activation increases intracellular cyclic GMP, promoting endochondral ossification and linear bone growth. This mechanism directly counteracts the fibroblast growth factor receptor 3 (FGFR3) signaling dysregulation that underlies achondroplasia pathophysiology.
Molecular Type/Modality: Small molecule; synthetic peptide analog.
Route of Administration: Subcutaneous daily injection.
Target: Natriuretic peptide receptor B (NPR-B); growth plate chondrocytes.
Formulations: Powder and solvent for solution for injection in three strengths: 0.4 mg, 0.56 mg, and 1.2 mg.
Related Therapies: Recombinant human growth hormone (off-label use in achondroplasia); supportive surgical and orthopedic interventions for complications.
First Approval: United States approval date not yet disclosed in available records; Australian approval May 2023; European Union approval November 2025.
Patent Status: Not yet disclosed.
Also known as: ACH, achondroplastic dwarfism
Prevalence: Prevalence at birth: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Achondroplasia is the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
ClinicalTrials.gov lists 46 registered studies for Achondroplasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (16), PHASE3 (4), PHASE2/PHASE3 (3), PHASE1 (2), PHASE1/PHASE2 (1), PHASE4 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007037), Orphanet — achondroplasia, NCT00001536, NCT01435629, NCT01516229, NCT01541306, NCT01590446, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Australian TGA Approval
Voxzogo approved in Australia with PBS listings (codes 13270K, 13274P, 13275Q) for achondroplasia.
European Union Approval
Voxzogo approved by European Medicines Agency (EMA/H/C/005475) for achondroplasia.
Phase 3 Long-Term Extension Study (NCT 2023-508864-31-00)
Open-label long-term extension study evaluating safety and efficacy of vosoritide in children with achondroplasia; ongoing.
The competitive landscape for achondroplasia treatment includes several approved therapies, though most are not specifically indicated for achondroplasia and represent off-label or supportive care approaches. Recombinant human growth hormone (approved by Xiyuan Hospital of China Academy of Chinese Medical Sciences) is used off-label in some achondroplasia cases but lacks specific indication approval and efficacy data in this population.
Bone metabolism agents approved in the musculo-skeletal space include ibandronic acid (Teva Pharma GmbH), alendronic acid formulations (Mylan, MSD), denosumab (Intas, marketed as Vysribli), and other bone-active agents (Corora, Aclasta, Evenity by Amgen; Osseor, Inductos, Osigraft). However, these therapies target osteoporosis, bone loss, or other skeletal conditions rather than achondroplasia specifically and do not address the underlying growth plate pathophysiology.
Crysvita (burosumab, KYOWA KIRIN AUSTRALIA PTY LTD) represents a precedent for rare skeletal dysplasia treatment but targets X-linked hypophosphatemia through FGF23 inhibition, a distinct mechanism and disease indication. Voxzogo's CNP receptor agonism represents a novel mechanistic approach with no direct competitors in the achondroplasia space. The absence of approved disease-modifying therapies for achondroplasia prior to vosoritide approval establishes Voxzogo as a category-defining agent with current competitive isolation in its indication.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Recombinant human growth hormone | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Approved |
| INFIGRATINIB | — | Fibroblast growth factor receptor inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Voxzogo approved under NDA 214938 (BIOMARIN PHARM); specific approval date not yet disclosed in available records.
European Union (EMA): Voxzogo approved November 17, 2025 (EMA/H/C/005475) by the European Medicines Agency. Marketing Authorization Holder: BioMarin International Limited.
Australia (TGA): Voxzogo approved May 1, 2023 with three PBS listings: code 13270K (0.4 mg), 13274P (0.56 mg), and 13275Q (1.2 mg). Sponsor: BioMarin Pharmaceutical Australia Pty Ltd. PBS listing indicates government reimbursement approval and pricing negotiation completion.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Expected Loss of Exclusivity: Not yet disclosed.
Voxzogo (vosoritide) is used to treat achondroplasia, the most common form of genetic dwarfism, in children. It is the first disease-modifying pharmacological therapy approved for this indication.
Yes, Voxzogo is approved in the United States (NDA 214938), European Union (EMA/H/C/005475, approved November 17, 2025), and Australia (TGA, approved May 1, 2023 with PBS listings).
Voxzogo is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) in growth plate cartilage, promoting bone growth and linear growth velocity in children with achondroplasia.
Voxzogo is developed and marketed by BioMarin Pharmaceutical Australia Pty Ltd (Australian sponsor) and BioMarin International Limited (European Marketing Authorization Holder).
The active ingredient is vosoritide, a synthetic C-type natriuretic peptide analog.
Voxzogo is administered as a subcutaneous (under the skin) daily injection.
Voxzogo is available in three strengths: 0.4 mg, 0.56 mg, and 1.2 mg powder and solvent for solution for injection.
A Phase 3 open-label long-term extension study (NCT 2023-508864-31-00) is currently ongoing to evaluate safety and efficacy in children with achondroplasia; results not yet reported.
Yes, Voxzogo is listed on the Australian Pharmaceutical Benefits Scheme (PBS) with three codes (13270K, 13274P, 13275Q), indicating government-subsidized access.
Achondroplasia is a rare genetic disorder causing severe growth restriction and skeletal abnormalities, affecting approximately 1 in 25,000 live births. It is the most common form of genetic dwarfism.
Voxzogo is currently the only approved disease-modifying therapy for achondroplasia. Recombinant human growth hormone is used off-label in some cases, but lacks specific indication approval for achondroplasia.
Voxzogo is classified under the Musculo-skeletal system (M05) therapeutic category and functions as a C-type natriuretic peptide receptor agonist.
Voxzogo is approved in the US, EU, and Australia. Current development activity includes a Phase 3 open-label long-term extension study evaluating safety and efficacy in children with achondroplasia.
Voxzogo is indicated for children with achondroplasia. The global achondroplasia population is estimated at approximately 250,000 individuals, with approximately 25,000 new cases annually.
The three PBS codes for Voxzogo are 13270K (0.4 mg), 13274P (0.56 mg), and 13275Q (1.2 mg).
Regulatory status in Japan (PMDA) and China (NMPA) has not yet been disclosed.
111-302 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: BioMarin's development strategy prioritizes long-term safety surveillance and real-world efficacy data collection through the Phase 3 extension study, positioning Voxzogo for sustained market presence and potential label expansions. The three-market approval (US, EU, Australia) establishes a strong geographic footprint in developed healthcare systems with robust reimbursement frameworks. PBS listing in Australia demonstrates successful health economic argument and payer acceptance.
Competitive Implications: Voxzogo currently faces no direct competitors in the achondroplasia indication, establishing market exclusivity. The absence of alternative disease-modifying therapies creates a category-defining opportunity. Off-label growth hormone use represents the only current pharmacological comparator, but lacks specific efficacy data and indication approval. This competitive isolation may persist through the extension study period and beyond, depending on competitor development timelines in achondroplasia.
Future Catalysts: Completion and publication of the Phase 3 long-term extension study (NCT 2023-508864-31-00) will provide critical safety and efficacy data supporting label maintenance and potential expansions. Regulatory approvals in Japan (PMDA) and China (NMPA) would significantly expand addressable market. Potential label expansion to adult achondroplasia populations or related skeletal dysplasias (hypochondroplasia, thanatophoric dysplasia) represents medium-term growth opportunities. Real-world evidence generation through post-marketing surveillance will inform clinical practice patterns and payer coverage decisions.
Expected Milestones: Ongoing Phase 3 extension study data reporting; potential PMDA and NMPA submissions; long-term safety and efficacy publications; potential label expansion discussions with regulatory agencies.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.